Sodium butyrate prevents lipopolysaccharide induced inflammation and restores the expression of tight junction protein in human epithelial Caco-2 cells

Cell Immunol. 2025 Feb:408:104912. doi: 10.1016/j.cellimm.2024.104912. Epub 2024 Dec 21.

Abstract

The gastrointestinal (GI) tract is susceptible to damage under high altitude hypoxic conditions, leading to gastrointestinal discomfort and intestinal barrier injury. Sodium butyrate, a short-chain fatty acid present as a metabolite in the gut, has emerged as a promising therapeutic agent due to its ability to act as an immunomodulatory agent and restore intestinal barrier integrity. This study aimed to explore the mechanism by which sodium butyrate exhibits anti inflammatory effect on intestinal epithelial cells. In vitro, Caco-2 epithelial cells and RAW 264.7 macrophages were used to investigate the protective role of sodium butyrate on Lipopolysaccharide (LPS) induced inflammation. Cell viability assays demonstrated that 1 mM (110.86 μg/mL) of sodium butyrate did not exhibit cytotoxicity on cells in vitro. Treatment with sodium butyrate suppressed reactive oxygen species levels and TNF-α production in LPS-stimulated macrophages, indicating its efficacy in mitigating inflammatory responses. Western blot analysis revealed that sodium butyrate attenuated the expression of iNOS in RAW 264.7 macrophage cells. Moreover, sodium butyrate also reversed the LPS induced over expression of HIF-1α, NLRP3, IL-1β as well as NF-kB in Caco-2 epithelial cells and also had a suppressive effect on IL-8 secretion after LPS stimulation. Immunocytochemistry demonstrated that sodium butyrate enhanced tight junction protein occludin expression in Caco-2 cells while also restoring the decreased permeability of the Caco-2 monolayer due to LPS. These results indicate that sodium butyrate may influence immune responses by suppressing inflammatory mediators and improving the integrity of the epithelial barrier. Understanding the intricate interactions between gut metabolites and host immune responses may help in the development of innovative therapeutic strategies to alleviate intestinal inflammation in high altitude environments.

Keywords: Cytokines; Gut immunity; Inflammasome; Inflammation; Sodium butyrate.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Butyric Acid* / pharmacology
  • Caco-2 Cells
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Inflammation* / metabolism
  • Interleukin-1beta / metabolism
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / metabolism
  • Lipopolysaccharides*
  • Macrophages / drug effects
  • Macrophages / immunology
  • Macrophages / metabolism
  • Mice
  • NF-kappa B / metabolism
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • RAW 264.7 Cells
  • Reactive Oxygen Species / metabolism
  • Tight Junction Proteins* / metabolism
  • Tight Junctions / drug effects
  • Tight Junctions / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Lipopolysaccharides
  • Butyric Acid
  • Tight Junction Proteins
  • Reactive Oxygen Species
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Nitric Oxide Synthase Type II
  • Tumor Necrosis Factor-alpha
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Interleukin-1beta
  • NF-kappa B
  • Anti-Inflammatory Agents